Brian Abrahams
Stock Analyst at RBC Capital
(2.15)
# 2,791
Out of 4,761 analysts
439
Total ratings
40.25%
Success rate
-5.18%
Average return
Main Sectors:
Stocks Rated by Brian Abrahams
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Maintains: Sector Perform | $407 → $408 | $484.24 | -15.74% | 50 | Feb 20, 2025 | |
| KPTI Karyopharm Therapeutics | Reiterates: Outperform | $3 | $0.60 | +401.34% | 11 | Feb 20, 2025 | |
| PTCT PTC Therapeutics | Maintains: Outperform | $60 → $63 | $50.69 | +24.28% | 18 | Feb 18, 2025 | |
| BIIB Biogen | Maintains: Outperform | $231 → $225 | $140.64 | +59.98% | 34 | Feb 13, 2025 | |
| GILD Gilead Sciences | Maintains: Sector Perform | $84 → $90 | $109.95 | -18.14% | 31 | Feb 12, 2025 | |
| INCY Incyte | Maintains: Sector Perform | $70 → $68 | $72.11 | -5.70% | 20 | Feb 11, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Sector Perform | $45 → $4 | $3.08 | +29.87% | 12 | Feb 10, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Sector Perform | $154 → $148 | $120.69 | +22.63% | 17 | Feb 7, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $139 → $143 | $137.75 | +3.81% | 2 | Feb 3, 2025 | |
| NAMS NewAmsterdam Pharma Company | Reiterates: Outperform | $40 | $18.57 | +115.40% | 1 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $108 → $132 | $128.60 | +2.64% | 19 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $20 → $1.5 | $1.38 | +8.70% | 15 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $31 | $7.59 | +308.43% | 4 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $4 → $1.5 | $0.53 | +183.02% | 5 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $48 → $2 | $1.78 | +12.36% | 11 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $1.80 | +1,511.11% | 5 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Perform | $4 | $7.31 | -45.28% | 21 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $9.21 | +8.58% | 15 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,260 → $1,215 | $700.33 | +73.49% | 30 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $32 → $30 | $26.74 | +12.19% | 11 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $182 | $106.28 | +71.25% | 31 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $82 | $8.18 | +902.44% | 7 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $55 | $39.73 | +38.43% | 13 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $28 → $24 | $15.56 | +54.24% | 9 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $13 → $12 | $11.06 | +8.50% | 14 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $22 | $7.63 | +188.34% | 9 | Jun 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $25 → $15 | $8.03 | +86.80% | 14 | Oct 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $12 → $9 | $1.99 | +352.26% | 3 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $21 → $33 | $47.37 | -30.34% | 3 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $42.59 | - | 4 | Dec 4, 2017 |
Vertex Pharmaceuticals
Feb 20, 2025
Maintains: Sector Perform
Price Target: $407 → $408
Current: $484.24
Upside: -15.74%
Karyopharm Therapeutics
Feb 20, 2025
Reiterates: Outperform
Price Target: $3
Current: $0.60
Upside: +401.34%
PTC Therapeutics
Feb 18, 2025
Maintains: Outperform
Price Target: $60 → $63
Current: $50.69
Upside: +24.28%
Biogen
Feb 13, 2025
Maintains: Outperform
Price Target: $231 → $225
Current: $140.64
Upside: +59.98%
Gilead Sciences
Feb 12, 2025
Maintains: Sector Perform
Price Target: $84 → $90
Current: $109.95
Upside: -18.14%
Incyte
Feb 11, 2025
Maintains: Sector Perform
Price Target: $70 → $68
Current: $72.11
Upside: -5.70%
Pliant Therapeutics
Feb 10, 2025
Downgrades: Sector Perform
Price Target: $45 → $4
Current: $3.08
Upside: +29.87%
Neurocrine Biosciences
Feb 7, 2025
Maintains: Sector Perform
Price Target: $154 → $148
Current: $120.69
Upside: +22.63%
Axsome Therapeutics
Feb 3, 2025
Maintains: Outperform
Price Target: $139 → $143
Current: $137.75
Upside: +3.81%
NewAmsterdam Pharma Company
Jan 28, 2025
Reiterates: Outperform
Price Target: $40
Current: $18.57
Upside: +115.40%
Jan 22, 2025
Downgrades: Sector Perform
Price Target: $108 → $132
Current: $128.60
Upside: +2.64%
Jan 10, 2025
Downgrades: Sector Perform
Price Target: $20 → $1.5
Current: $1.38
Upside: +8.70%
Jan 9, 2025
Reiterates: Outperform
Price Target: $31
Current: $7.59
Upside: +308.43%
Dec 20, 2024
Maintains: Sector Perform
Price Target: $4 → $1.5
Current: $0.53
Upside: +183.02%
Dec 20, 2024
Downgrades: Sector Perform
Price Target: $48 → $2
Current: $1.78
Upside: +12.36%
Nov 22, 2024
Reiterates: Outperform
Price Target: $29
Current: $1.80
Upside: +1,511.11%
Nov 21, 2024
Upgrades: Sector Perform
Price Target: $4
Current: $7.31
Upside: -45.28%
Nov 5, 2024
Reiterates: Outperform
Price Target: $10
Current: $9.21
Upside: +8.58%
Nov 1, 2024
Maintains: Outperform
Price Target: $1,260 → $1,215
Current: $700.33
Upside: +73.49%
Nov 1, 2024
Maintains: Sector Perform
Price Target: $32 → $30
Current: $26.74
Upside: +12.19%
Oct 21, 2024
Reiterates: Outperform
Price Target: $182
Current: $106.28
Upside: +71.25%
Sep 20, 2024
Reiterates: Outperform
Price Target: $82
Current: $8.18
Upside: +902.44%
Sep 3, 2024
Reiterates: Outperform
Price Target: $55
Current: $39.73
Upside: +38.43%
Aug 9, 2024
Maintains: Sector Perform
Price Target: $28 → $24
Current: $15.56
Upside: +54.24%
Aug 6, 2024
Maintains: Sector Perform
Price Target: $13 → $12
Current: $11.06
Upside: +8.50%
Jun 5, 2024
Reiterates: Outperform
Price Target: $22
Current: $7.63
Upside: +188.34%
Oct 2, 2023
Maintains: Sector Perform
Price Target: $25 → $15
Current: $8.03
Upside: +86.80%
Mar 31, 2022
Maintains: Sector Perform
Price Target: $12 → $9
Current: $1.99
Upside: +352.26%
Nov 3, 2021
Maintains: Sector Perform
Price Target: $21 → $33
Current: $47.37
Upside: -30.34%
Dec 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $42.59
Upside: -